Research advances in diagnosis and treatment of transthyretin cardiac amyloidosis
Transthyretin cardiac amyloidosis(ATTR-CA)has been considered as a rare cardiac dysfunction with occult onset,rapid progression and high mortality,caused by the accumulation of transthyretin fibrils in the myocardium.Recently,with the development of diagnostic techniques,its detection rate has been increasing.The continuous emergence of various small molecule drugs has also changed the previous situation of lacking therapeutic agents,and its mortality has been reduced.This paper mainly summarizes the latest advances in the diagnosis and treatment of ATTR-CA in recent years.
amyloidosiscardiomyopathytransthyretintransthyretin cardiac amyloidosiscardiac magnetic resonancesmall molecule drug
国家科技期刊平台
NSTL
万方数据
